The Sting Challenge Test Shows High Negative Predictive Value in Patients Receiving Venom Immunotherapy.

IF 4.8 3区医学 Q1 ALLERGY

Journal of Investigational Allergology and Clinical Immunology Pub Date : 2025-07-23 DOI:10.18176/jiaci.1086

T Alfaya Arias, A Vega Castro, D Garnica-Velandia, J Macías Iglesias, J Pereira González, N Blanco Toledano, A Puig Fuentes, G Vicens-Novell, M Bermúdez Bejarano, A Tsopana, L Marquès, D González-de-Olano, E Pérez-Fernández, B Ruiz-León

{"title":"The Sting Challenge Test Shows High Negative Predictive Value in Patients Receiving Venom Immunotherapy.","authors":"T Alfaya Arias, A Vega Castro, D Garnica-Velandia, J Macías Iglesias, J Pereira González, N Blanco Toledano, A Puig Fuentes, G Vicens-Novell, M Bermúdez Bejarano, A Tsopana, L Marquès, D González-de-Olano, E Pérez-Fernández, B Ruiz-León","doi":"10.18176/jiaci.1086","DOIUrl":null,"url":null,"abstract":"Background and objectives: The sting challenge test (SCT) is regarded as the most reliable method for assessing the effectiveness of venom immunotherapy (VIT). However, its predictive value in patients undergoing VIT is unclear. This study aims to evaluate the predictive value of the SCT.Methods: A multicenter retrospective observational study was conducted on patients receiving VIT who underwent SCT. The study gathered data on patient demographics, diagnosis, immunotherapy details, outcomes of the SCT, and subsequent field stings.Results: A total of 261 patients were included, and 372 SCTs were recorded. Most patients (75.1%) were men. Mastocytosis was confirmed in 7.7%. The final diagnosis was allergy to Apis mellifera (48.7%), Polistes dominula (36.8%), Vespula species (2.7%), and P dominula plus Vespula species (10.7%). SCTs were performed with Apis in 61.6% overall, Polistes in 34.1%, and Vespula in 4.3%. Most of the SCT results were negative (95.7%). A total of 306 field stings were recorded for 146 patients (56.2%); of these, 95.1% were negative. Among these 146 affected patients, 137 had a negative SCT result, and 130 of these also had a subsequent negative field sting, resulting in a negative predictive value (NPV) for the SCT of 94.9%. Of the patients who experienced a field sting, 9 had a positive SCT, and only 3 had a positive field sting, resulting in a positive predictive value of 33.3%.Conclusions: SCT is safe, and the high NPV emphasizes the usefulness of this test in assessing the effectiveness of VIT.","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"0"},"PeriodicalIF":4.8000,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Investigational Allergology and Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18176/jiaci.1086","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objectives: The sting challenge test (SCT) is regarded as the most reliable method for assessing the effectiveness of venom immunotherapy (VIT). However, its predictive value in patients undergoing VIT is unclear. This study aims to evaluate the predictive value of the SCT.

Methods: A multicenter retrospective observational study was conducted on patients receiving VIT who underwent SCT. The study gathered data on patient demographics, diagnosis, immunotherapy details, outcomes of the SCT, and subsequent field stings.

Results: A total of 261 patients were included, and 372 SCTs were recorded. Most patients (75.1%) were men. Mastocytosis was confirmed in 7.7%. The final diagnosis was allergy to Apis mellifera (48.7%), Polistes dominula (36.8%), Vespula species (2.7%), and P dominula plus Vespula species (10.7%). SCTs were performed with Apis in 61.6% overall, Polistes in 34.1%, and Vespula in 4.3%. Most of the SCT results were negative (95.7%). A total of 306 field stings were recorded for 146 patients (56.2%); of these, 95.1% were negative. Among these 146 affected patients, 137 had a negative SCT result, and 130 of these also had a subsequent negative field sting, resulting in a negative predictive value (NPV) for the SCT of 94.9%. Of the patients who experienced a field sting, 9 had a positive SCT, and only 3 had a positive field sting, resulting in a positive predictive value of 33.3%.

Conclusions: SCT is safe, and the high NPV emphasizes the usefulness of this test in assessing the effectiveness of VIT.

查看原文本刊更多论文

在接受毒液免疫治疗的患者中，刺痛攻击试验显示出很高的阴性预测值。

背景与目的：刺激试验（SCT）被认为是评估毒液免疫治疗（VIT）有效性的最可靠的方法。然而，其对VIT患者的预测价值尚不清楚。本研究旨在评估SCT的预测价值。方法：对行SCT的VIT患者进行多中心回顾性观察研究。该研究收集了患者人口统计、诊断、免疫治疗细节、SCT结果和随后的野外针刺等数据。结果：共纳入261例患者，记录了372例sct。大多数患者为男性（75.1%）。肥大细胞增多症占7.7%。最终诊断为对蜜蜂过敏（48.7%），其次是多花蜂（36.8%），小黄蜂（2.7%）和多花蜂+小黄蜂（10.7%）。使用api进行sct的比例为61.6%，Polistes为34.1%，Vespula为4.3%。绝大多数SCT结果为阴性（95.7%）。146例（56.2%）患者共录得306次野外蜇伤；其中，95.1%为阴性。在146例受影响的患者中，137例SCT结果为阴性，其中130例随后也有阴性场刺，导致SCT的阴性预测值（NPV）为94.9%。在经历野刺痛的患者中，9例SCT阳性，只有3例野刺痛阳性，阳性预测值为33.3%。结论：SCT是安全的，高NPV强调了该测试在评估VIT有效性方面的有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Investigational Allergology and Clinical Immunology 医学-过敏

CiteScore

7.10

自引率

9.70%

发文量

135

审稿时长

6-12 weeks

期刊介绍： The Journal of Investigational Allergology and Clinical Immunology (J Investig Allergol Clin Immunol) provides an attractive and very active forum for basic and clinical research in allergology and clinical immunology.Journal of Investigational Allergology and Clinical Immunology publishes original works, reviews, short communications and opinions.